Neurological Disorders

BOSTON SCIENTIFIC LAUNCHES VERCISE GENUS™ DBS SYSTEM IN EUROPE-
Sept 10, 2020

Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in Europe. Featuring full-body MRI conditionaland Bluetooth capabilities across the portfolio…

Read more >

Boston scientific announces CE mark approval of the Vercise™ Neural Navigator 3 Programming Software -
Oct 17, 2019

Boston Scientific Corporation announced the CE Mark approval of the Vercise™ Neural Navigator 3 directional Deep Brain Stimulation (DBS) programming software - the first system that integrates patient-specific 3D brain anatomy and…

Read more

Boston Scientific launches GUIDE™ XT System for Visualization of Deep Brain Stimulation - Sep 26, 2018

Boston Scientific Corporation today announced the launch of the GUIDE™ XT  System for visualization of Deep Brain Stimulation (DBS) in Europe. The GUIDE XT System is the first DBS visualization system built for…

Read more

SEE ALL PRESS RELEASES

2014 | 2015 | 2016 | 2018

BOSTON SCIENTIFIC LAUNCHES VERCISE GENUS™ DBS SYSTEM IN EUROPE-
Sept 10, 2020

Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in Europe. Featuring full-body MRI conditionaland Bluetooth capabilities across the portfolio…

Read more

BOSTON SCIENTIFIC LAUNCHES WAVEWRITER ALPHA™ SPINAL CORD STIMULATOR SYSTEMS IN EUROPE-

SCS portfolio features full-body MRI conditional devices that combine therapy options for personalized pain relief

Sept 30, 2020

Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The portfolio, consisting of four MRI conditionali, Bluetooth-enabled implantable pulse generators (IPGs), offers expanded personalization based on patient needs, including rechargeable and non-rechargeable options, and access to waveforms that can cover multiple areas of pain…

Read more >

Media Contacts

Rosie Ireland
Corporate Communications
+44 7585403359
rosie.ireland@bsci.com

Company Profile
Top